REPLIGEN CORP (RGEN) Fundamental Analysis & Valuation

NASDAQ:RGEN • US7599161095

119.23 USD
-2.56 (-2.1%)
At close: Mar 11, 2026
119.23 USD
0 (0%)
After Hours: 3/11/2026, 4:30:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This RGEN fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

5

Overall RGEN gets a fundamental rating of 5 out of 10. We evaluated RGEN against 57 industry peers in the Life Sciences Tools & Services industry. RGEN is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. RGEN is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

5

1. RGEN Profitability Analysis

1.1 Basic Checks

  • RGEN had positive earnings in the past year.
  • RGEN had a positive operating cash flow in the past year.
  • RGEN had positive earnings in 4 of the past 5 years.
  • In the past 5 years RGEN always reported a positive cash flow from operatings.
RGEN Yearly Net Income VS EBIT VS OCF VS FCFRGEN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M 100M 150M

1.2 Ratios

  • RGEN's Return On Assets of 1.66% is fine compared to the rest of the industry. RGEN outperforms 66.67% of its industry peers.
  • RGEN's Return On Equity of 2.32% is fine compared to the rest of the industry. RGEN outperforms 68.42% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 1.65%, RGEN is in line with its industry, outperforming 59.65% of the companies in the same industry.
  • The Average Return On Invested Capital over the past 3 years for RGEN is significantly below the industry average of 11.85%.
  • The 3 year average ROIC (1.45%) for RGEN is below the current ROIC(1.65%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 1.66%
ROE 2.32%
ROIC 1.65%
ROA(3y)0.67%
ROA(5y)2.96%
ROE(3y)0.95%
ROE(5y)3.98%
ROIC(3y)1.45%
ROIC(5y)3.72%
RGEN Yearly ROA, ROE, ROICRGEN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2 4 6 8

1.3 Margins

  • RGEN has a better Profit Margin (6.62%) than 70.18% of its industry peers.
  • In the last couple of years the Profit Margin of RGEN has declined.
  • RGEN's Operating Margin of 8.03% is fine compared to the rest of the industry. RGEN outperforms 66.67% of its industry peers.
  • In the last couple of years the Operating Margin of RGEN has declined.
  • The Gross Margin of RGEN (52.65%) is better than 66.67% of its industry peers.
  • RGEN's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 8.03%
PM (TTM) 6.62%
GM 52.65%
OM growth 3Y-31%
OM growth 5Y-16.8%
PM growth 3Y-34.16%
PM growth 5Y-16.54%
GM growth 3Y-2.53%
GM growth 5Y-1.65%
RGEN Yearly Profit, Operating, Gross MarginsRGEN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. RGEN Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so RGEN is destroying value.
  • RGEN has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for RGEN has been increased compared to 5 years ago.
  • Compared to 1 year ago, RGEN has an improved debt to assets ratio.
RGEN Yearly Shares OutstandingRGEN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M
RGEN Yearly Total Debt VS Total AssetsRGEN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B 2.5B

2.2 Solvency

  • An Altman-Z score of 5.82 indicates that RGEN is not in any danger for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 5.82, RGEN belongs to the top of the industry, outperforming 89.47% of the companies in the same industry.
  • RGEN has a debt to FCF ratio of 5.91. This is a neutral value as RGEN would need 5.91 years to pay back of all of its debts.
  • RGEN's Debt to FCF ratio of 5.91 is fine compared to the rest of the industry. RGEN outperforms 68.42% of its industry peers.
  • A Debt/Equity ratio of 0.26 indicates that RGEN is not too dependend on debt financing.
  • RGEN has a Debt to Equity ratio (0.26) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.26
Debt/FCF 5.91
Altman-Z 5.82
ROIC/WACC0.15
WACC10.78%
RGEN Yearly LT Debt VS Equity VS FCFRGEN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B

2.3 Liquidity

  • A Current Ratio of 8.37 indicates that RGEN has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 8.37, RGEN belongs to the top of the industry, outperforming 94.74% of the companies in the same industry.
  • A Quick Ratio of 7.12 indicates that RGEN has no problem at all paying its short term obligations.
  • RGEN has a better Quick ratio (7.12) than 91.23% of its industry peers.
Industry RankSector Rank
Current Ratio 8.37
Quick Ratio 7.12
RGEN Yearly Current Assets VS Current LiabilitesRGEN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. RGEN Growth Analysis

3.1 Past

  • RGEN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 15.54%, which is quite good.
  • The Earnings Per Share has been growing slightly by 0.60% on average over the past years.
  • Looking at the last year, RGEN shows a decrease in Revenue. The Revenue has decreased by -6.05% in the last year.
  • The Revenue has been growing by 15.05% on average over the past years. This is quite good.
EPS 1Y (TTM)15.54%
EPS 3Y-19.52%
EPS 5Y0.6%
EPS Q2Q%11.36%
Revenue 1Y (TTM)-6.05%
Revenue growth 3Y-2.7%
Revenue growth 5Y15.05%
Sales Q2Q%18.12%

3.2 Future

  • The Earnings Per Share is expected to grow by 26.07% on average over the next years. This is a very strong growth
  • The Revenue is expected to grow by 15.56% on average over the next years. This is quite good.
EPS Next Y16.45%
EPS Next 2Y20.77%
EPS Next 3Y22.86%
EPS Next 5Y26.07%
Revenue Next Year12.66%
Revenue Next 2Y13.68%
Revenue Next 3Y14.28%
Revenue Next 5Y15.56%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
RGEN Yearly Revenue VS EstimatesRGEN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 500M 1B 1.5B 2B 2.5B
RGEN Yearly EPS VS EstimatesRGEN Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2 4 6 8

More info and screens

Find the best growth stocksShow best growing peers

2

4. RGEN Valuation Analysis

4.1 Price/Earnings Ratio

  • RGEN is valuated quite expensively with a Price/Earnings ratio of 69.73.
  • RGEN's Price/Earnings is on the same level as the industry average.
  • When comparing the Price/Earnings ratio of RGEN to the average of the S&P500 Index (26.25), we can say RGEN is valued expensively.
  • Based on the Price/Forward Earnings ratio of 59.87, the valuation of RGEN can be described as expensive.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of RGEN is on the same level as its industry peers.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 24.39, RGEN is valued quite expensively.
Industry RankSector Rank
PE 69.73
Fwd PE 59.87
RGEN Price Earnings VS Forward Price EarningsRGEN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • The rest of the industry has a similar Enterprise Value to EBITDA ratio as RGEN.
  • RGEN's Price/Free Cash Flow is on the same level as the industry average.
Industry RankSector Rank
P/FCF 73.25
EV/EBITDA 46.6
RGEN Per share dataRGEN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • A more expensive valuation may be justified as RGEN's earnings are expected to grow with 22.86% in the coming years.
PEG (NY)4.24
PEG (5Y)117.13
EPS Next 2Y20.77%
EPS Next 3Y22.86%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. RGEN Dividend Analysis

5.1 Amount

  • RGEN does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

RGEN Fundamentals: All Metrics, Ratios and Statistics

REPLIGEN CORP

NASDAQ:RGEN (3/11/2026, 4:30:02 PM)

After market: 119.23 0 (0%)

119.23

-2.56 (-2.1%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-24
Earnings (Next)04-27
Inst Owners112.04%
Inst Owner Change0.02%
Ins Owners0.39%
Ins Owner Change-4.1%
Market Cap6.72B
Revenue(TTM)738.26M
Net Income(TTM)48.89M
Analysts81.43
Price Target191.52 (60.63%)
Short Float %7.69%
Short Ratio5.59
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)8.52%
Min EPS beat(2)7.78%
Max EPS beat(2)9.25%
EPS beat(4)3
Avg EPS beat(4)5.23%
Min EPS beat(4)-6.83%
Max EPS beat(4)10.73%
EPS beat(8)5
Avg EPS beat(8)5.28%
EPS beat(12)8
Avg EPS beat(12)7.82%
EPS beat(16)12
Avg EPS beat(16)10.63%
Revenue beat(2)2
Avg Revenue beat(2)1.33%
Min Revenue beat(2)0.58%
Max Revenue beat(2)2.07%
Revenue beat(4)4
Avg Revenue beat(4)1.51%
Min Revenue beat(4)0.58%
Max Revenue beat(4)2.15%
Revenue beat(8)4
Avg Revenue beat(8)-0.01%
Revenue beat(12)4
Avg Revenue beat(12)-0.88%
Revenue beat(16)7
Avg Revenue beat(16)0.5%
PT rev (1m)-1.5%
PT rev (3m)-0.1%
EPS NQ rev (1m)-16%
EPS NQ rev (3m)-16.54%
EPS NY rev (1m)-6.29%
EPS NY rev (3m)-5.91%
Revenue NQ rev (1m)0.46%
Revenue NQ rev (3m)0.33%
Revenue NY rev (1m)0.2%
Revenue NY rev (3m)0.1%
Valuation
Industry RankSector Rank
PE 69.73
Fwd PE 59.87
P/S 9.1
P/FCF 73.25
P/OCF 57.2
P/B 3.19
P/tB 11.09
EV/EBITDA 46.6
EPS(TTM)1.71
EY1.43%
EPS(NY)1.99
Fwd EY1.67%
FCF(TTM)1.63
FCFY1.37%
OCF(TTM)2.08
OCFY1.75%
SpS13.11
BVpS37.39
TBVpS10.75
PEG (NY)4.24
PEG (5Y)117.13
Graham Number37.93
Profitability
Industry RankSector Rank
ROA 1.66%
ROE 2.32%
ROCE 2.11%
ROIC 1.65%
ROICexc 2.27%
ROICexgc 8.52%
OM 8.03%
PM (TTM) 6.62%
GM 52.65%
FCFM 12.42%
ROA(3y)0.67%
ROA(5y)2.96%
ROE(3y)0.95%
ROE(5y)3.98%
ROIC(3y)1.45%
ROIC(5y)3.72%
ROICexc(3y)2.01%
ROICexc(5y)5.28%
ROICexgc(3y)7.46%
ROICexgc(5y)30.51%
ROCE(3y)1.85%
ROCE(5y)4.75%
ROICexgc growth 3Y-45.78%
ROICexgc growth 5YN/A
ROICexc growth 3Y-39.51%
ROICexc growth 5Y-19.39%
OM growth 3Y-31%
OM growth 5Y-16.8%
PM growth 3Y-34.16%
PM growth 5Y-16.54%
GM growth 3Y-2.53%
GM growth 5Y-1.65%
F-Score6
Asset Turnover0.25
Health
Industry RankSector Rank
Debt/Equity 0.26
Debt/FCF 5.91
Debt/EBITDA 3.93
Cap/Depr 32.68%
Cap/Sales 3.49%
Interest Coverage 250
Cash Conversion 85.06%
Profit Quality 187.52%
Current Ratio 8.37
Quick Ratio 7.12
Altman-Z 5.82
F-Score6
WACC10.78%
ROIC/WACC0.15
Cap/Depr(3y)44.28%
Cap/Depr(5y)98.33%
Cap/Sales(3y)4.79%
Cap/Sales(5y)7.2%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)15.54%
EPS 3Y-19.52%
EPS 5Y0.6%
EPS Q2Q%11.36%
EPS Next Y16.45%
EPS Next 2Y20.77%
EPS Next 3Y22.86%
EPS Next 5Y26.07%
Revenue 1Y (TTM)-6.05%
Revenue growth 3Y-2.7%
Revenue growth 5Y15.05%
Sales Q2Q%18.12%
Revenue Next Year12.66%
Revenue Next 2Y13.68%
Revenue Next 3Y14.28%
Revenue Next 5Y15.56%
EBIT growth 1Y282.37%
EBIT growth 3Y-32.87%
EBIT growth 5Y-4.28%
EBIT Next Year81.24%
EBIT Next 3Y41.89%
EBIT Next 5Y37.01%
FCF growth 1Y-36.98%
FCF growth 3Y3.04%
FCF growth 5Y20.36%
OCF growth 1Y-33.06%
OCF growth 3Y-11.97%
OCF growth 5Y13.4%

REPLIGEN CORP / RGEN FAQ

Can you provide the ChartMill fundamental rating for REPLIGEN CORP?

ChartMill assigns a fundamental rating of 5 / 10 to RGEN.


What is the valuation status for RGEN stock?

ChartMill assigns a valuation rating of 2 / 10 to REPLIGEN CORP (RGEN). This can be considered as Overvalued.


What is the profitability of RGEN stock?

REPLIGEN CORP (RGEN) has a profitability rating of 5 / 10.


What is the financial health of REPLIGEN CORP (RGEN) stock?

The financial health rating of REPLIGEN CORP (RGEN) is 7 / 10.


What is the earnings growth outlook for REPLIGEN CORP?

The Earnings per Share (EPS) of REPLIGEN CORP (RGEN) is expected to grow by 16.45% in the next year.